Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01934582 · ClinicalTrials.gov registry record · Phase 3
A Pharmacokinetic Substudy of the TDE-PH-304 Protocol
A Phase 3 study, sponsored by United Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 13
- Enrollment target
NCT01934582 is a Phase 3 study that has completed, run by United Therapeutics. The registered enrollment target is 13 participants.
The verdict
NCT01934582, a Phase 3 study, has completed, sponsored by United Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 13 participants
- Enrollment target
Study Summary
A sub-study to the TDE-PH-304 protocol to assess the pharmacokinetics of patients transitioning from a twice daily dosing regimen of oral treprostinil to a three times daily dosing regimen.
Interventions
- DRUG UT-15C SR
- DRUG treprostinil diethanolamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2013-08 |
| Est. Completion | 2013-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01934582
The ClinicalTrials.gov registry entry for NCT01934582 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is United Therapeutics, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which UT-15C SR is the first listed.
NCT01934582 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01934582 about?
NCT01934582 is a clinical study titled "A Pharmacokinetic Substudy of the TDE-PH-304 Protocol". A sub-study to the TDE-PH-304 protocol to assess the pharmacokinetics of patients transitioning from a twice daily dosing regimen of oral treprostinil to a three times daily dosing regimen.
What is the current status of trial NCT01934582?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 13 participants. The study started on 2013-08. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01934582?
The interventions under investigation include: UT-15C SR (DRUG), treprostinil diethanolamine (DRUG).
Who is sponsoring clinical trial NCT01934582?
This trial is sponsored by United Therapeutics, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.